STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. insider filing reports a tax-related share withholding by a senior executive. On 11/13/2025, the Chief Executive Officer and Chairperson had 3,283 shares of common stock withheld by the company at a price of $4.18 per share to cover tax obligations arising from the vesting of restricted stock units. The filing states that no shares were sold in the market as a result of this vesting and related tax withholding. Following this transaction, the reporting person beneficially owns 607,822 shares directly and 442,765 shares indirectly through the DPH 2008 Trust.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hochman David P

(Last) (First) (Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE

(Street)
NEW HOPE PA 18938

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 11/13/2025 F(1) 3,283 D $4.18 607,822 D
Common Stock 11/13/2025 F(1) 3,283 D $4.18 442,765 I By the DPH 2008 Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations.
Remarks:
Chief Executive Officer and Chairperson
/s/ Andrew Taylor, Attorney-in-Fact 11/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OBIO report in this Form 4?

The Form 4 reports that on 11/13/2025, an executive of Orchestra BioMed Holdings, Inc. (OBIO) had 3,283 shares of common stock withheld by the company to satisfy tax withholding obligations related to vesting restricted stock units.

Were any OBIO shares sold in the market in this transaction?

No. The filing explains that the 3,283 shares were withheld by the issuer to satisfy tax obligations from restricted stock unit vesting and that no shares were sold in the market as a result.

How many OBIO shares does the reporting person own after the transaction?

After the transaction, the reporting person beneficially owns 607,822 shares of OBIO common stock directly and 442,765 shares indirectly through the DPH 2008 Trust.

What was the price used for the OBIO tax withholding shares?

The shares withheld to cover taxes were valued at $4.18 per share of Orchestra BioMed Holdings, Inc. common stock.

What is the role of the reporting person at Orchestra BioMed Holdings, Inc.?

The reporting person is identified as both Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc., and is also listed as a Director.

Is this OBIO Form 4 filed by one person or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, not by more than one reporting person.

Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

OBIO Latest News

OBIO Latest SEC Filings

OBIO Stock Data

222.47M
42.51M
16.13%
34.97%
1.43%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
NEW HOPE